---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001126"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:51:34.373610+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Celldex reports Q4 2024 net loss of $47.1M; cash $725.3M; Phase 3 CSU studies enrolling

## Summary
- Cash, equivalents and securities $725.3M at Dec 31, 2024; company funded through 2027.
- Q4 2024 net loss $47.1M ($0.71/sh) vs $43.3M ($0.83/sh) Q4 2023; R&D expenses $46.9M.
- Phase 3 CSU studies EMBARQ-CSU1/2 enrolling ~915 patients each across 40 countries.
- Phase 3 CIndU program expected to start in 2025; Phase 2 EoE study fully accrued.
- Phase 1 CDX-622 (SCF/TSLP bispecific) initiated; multiple data readouts expected in 2025.

## SEC filing metadata
- accession: 0001171843-25-001126
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184325001126/0001171843-25-001126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184325001126/f8k_022725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001126
- JSON: https://secwatch.observer/filing/0001171843-25-001126.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.